| Nov 14 |
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 12 |
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M
|
| Nov 12 |
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 12 |
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 7 |
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
|
| Nov 6 |
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
|
| Nov 5 |
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
|
| Oct 4 |
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
|
| Aug 29 |
TScan Therapeutics to Participate in Upcoming Investor Conferences
|
| Aug 29 |
Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
|
